Literature DB >> 26240746

Reducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study.

Peter Hjorth1, Reinhold Kilian2, Helle Østermark Sørensen3, Susan Engelbrechsen Eriksen4, Annette Sofie Davidsen5, Signe Olrik Wallenstein Jensen3, Povl Munk-Jørgensen6.   

Abstract

BACKGROUND: Many patients with mental illness receive psychotropic medicine in high dosages and from more than one drug. One of the consequences of this practice is obesity, which is a contributing factor to increased physical morbidity and premature death.
METHODS: Our study was a cluster-randomized intervention study involving 6 facilities and 174 patients diagnosed with severe mental illnesses (73% schizophrenia). The intervention period was 12 months and consisted of teaching sessions with the staff and evaluating the patients' intake of psychotropic medication. At index, 44% met criteria for obesity and 76% met criteria for overweight. Waist circumferences were 108 cm for men and 108 cm for women. Olanzapine, clozapine and quetiapine were the most common prescribed antipsychotics. Mean values of daily doses of antipsychotic were 2.5.
RESULTS: The intervention showed no significant differences between the intervention and control group regarding psychotropic treatment. At follow up, independent of intervention, patients receiving antipsychotic polypharmacy had a larger waist circumference compared with patients receiving antipsychotic monotherapy of 9.8 cm (1.5-18.1) (p = 0.028). DISCUSSION AND
CONCLUSION: We found both a high prevalence of obesity and that the patients received treatment with antipsychotic polypharmaceutics in high dosages. Active awareness did not change practice and we must think of other ways to restrict treatment with psychotropics in this group of patients.

Entities:  

Keywords:  cluster randomized intervention; mental illness; obesity; psychotropic polypharmacy

Year:  2015        PMID: 26240746      PMCID: PMC4521442          DOI: 10.1177/2045125314565361

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  26 in total

Review 1.  Body weight changes associated with psychopharmacology.

Authors:  Yelena Vanina; Anna Podolskaya; Karim Sedky; Hasan Shahab; Abufarah Siddiqui; Firoz Munshi; Steven Lippmann
Journal:  Psychiatr Serv       Date:  2002-07       Impact factor: 3.084

Review 2.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

4.  Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).

Authors:  Y-T Xiang; C-Y Wang; T-M Si; E H M Lee; Y-L He; G S Ungvari; H F K Chiu; S-Y Yang; M-Y Chong; C-H Tan; E-H Kua; S Fujii; K Sim; K H Yong; J K Trivedi; E-K Chung; P Udomratn; K-Y Chee; N Sartorius; N Shinfuku
Journal:  Pharmacopsychiatry       Date:  2011-10-11       Impact factor: 5.788

5.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 6.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 7.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Physical illness and schizophrenia: a review of the literature.

Authors:  S Leucht; T Burkard; J Henderson; M Maj; N Sartorius
Journal:  Acta Psychiatr Scand       Date:  2007-11       Impact factor: 6.392

9.  Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.

Authors:  Yen-Li Goh; Kok Han Seng; Alex Su Hsin Chuan; Hong Choon Chua
Journal:  Perm J       Date:  2011

10.  Cost of antipsychotic polypharmacy in the treatment of schizophrenia.

Authors:  Baojin Zhu; Haya Ascher-Svanum; Douglas E Faries; Christoph U Correll; John M Kane
Journal:  BMC Psychiatry       Date:  2008-04-04       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.